Moleculin Biotech, Inc. has been told it might be removed from Nasdaq because its stock price is too low.

MBRX · Moleculin Biotech, Inc.

The AI's read

Nasdaq notified Moleculin that its share price was below $1 for 30 consecutive business days and the company cannot use the usual 180-day cure because of a recent reverse split. That ineligibility raises the chance of delisting, and although a hearing will pause any suspension, the panel may still deny continued listing.